Avacta Group PLC Share Consolidation (9470M)
January 26 2016 - 3:05AM
UK Regulatory
TIDMAVCT
RNS Number : 9470M
Avacta Group PLC
26 January 2016
26 January 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Share Consolidation
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that the one for
one hundred consolidation of Avacta's ordinary shares of 0.1 pence
each, approved by shareholders at its Annual General Meeting on 25
January 2016, has become effective today. The consolidation has
increased the market price and decreased the number of shares in
issue.
Following the consolidation, the Company now has a total of
67,462,959 ordinary shares of 10 pence each in issue, each with
voting rights. No Ordinary Shares are held in Treasury.
The above figure of 67,462,959 shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Rules and Transparency Rules.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
Numis Securities Limited Tel: +44 (0)
Michael Meade / Freddie Barnfield 207 260 1000
- Nominated Adviser www.numiscorp.com
James Black - Corporate Broking
WG Partners Tel: +44 (0)
David Wilson 203 705 9318
Nigel Barnes Tel: +44 (0)
Claes Spang 203 705 9217
www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on oncology and bleeding disorders as well as
several partnered development programmes. Avacta is commercialising
Affimer reagents through custom Affimer services to provide bespoke
solutions to customers and via a growing on-line catalogue of
Affimer reagents.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEXELLLQFFEBBX
(END) Dow Jones Newswires
January 26, 2016 03:05 ET (08:05 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024